Wedmont Private Capital purchased a new stake in The Cooper Companies, Inc. (NYSE:COO – Get Rating) during the fourth quarter, according to its most recent 13F filing with the SEC. The firm purchased 804 shares of the medical device company’s stock, valued at approximately $278,000.
A number of other institutional investors have also modified their holdings of the company. CI Investments Inc. boosted its stake in Cooper Companies by 60.7% in the 3rd quarter. CI Investments Inc. now owns 135 shares of the medical device company’s stock worth $36,000 after purchasing an additional 51 shares in the last quarter. Standard Family Office LLC acquired a new stake in Cooper Companies in the 3rd quarter worth approximately $37,000. General Partner Inc. acquired a new stake in Cooper Companies in the 4th quarter worth approximately $37,000. Picton Mahoney Asset Management acquired a new stake in Cooper Companies in the 3rd quarter worth approximately $58,000. Finally, Wipfli Financial Advisors LLC acquired a new stake in Cooper Companies in the 3rd quarter worth approximately $63,000. 96.78% of the stock is currently owned by institutional investors.
Insider Buying and Selling
In related news, COO Gerard H. Warner III sold 1,216 shares of the business’s stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $340.53, for a total value of $414,084.48. Following the completion of the sale, the chief operating officer now owns 1,290 shares of the company’s stock, valued at approximately $439,283.70. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other news, COO Gerard H. Warner III sold 1,216 shares of the company’s stock in a transaction on Thursday, March 9th. The shares were sold at an average price of $340.53, for a total transaction of $414,084.48. Following the completion of the sale, the chief operating officer now owns 1,290 shares of the company’s stock, valued at $439,283.70. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Robert S. Weiss sold 37,510 shares of the company’s stock in a transaction on Tuesday, March 7th. The stock was sold at an average price of $337.72, for a total transaction of $12,667,877.20. Following the sale, the director now directly owns 70,000 shares of the company’s stock, valued at approximately $23,640,400. The disclosure for this sale can be found here. In the last quarter, insiders sold 39,726 shares of company stock valued at $13,426,262. 2.00% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Cooper Companies Price Performance
NYSE:COO opened at $341.50 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.72 and a quick ratio of 1.00. The firm has a market cap of $16.89 billion, a price-to-earnings ratio of 45.23, a price-to-earnings-growth ratio of 2.42 and a beta of 0.89. The company has a 50 day moving average price of $342.01 and a 200-day moving average price of $312.47. The Cooper Companies, Inc. has a 1-year low of $244.21 and a 1-year high of $429.89.
Cooper Companies (NYSE:COO – Get Rating) last posted its earnings results on Thursday, March 2nd. The medical device company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.66 by $0.24. The firm had revenue of $858.50 million during the quarter, compared to analyst estimates of $834.90 million. Cooper Companies had a net margin of 11.10% and a return on equity of 8.39%. The business’s quarterly revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the firm earned $3.24 EPS. Equities research analysts forecast that The Cooper Companies, Inc. will post 12.74 EPS for the current year.
Cooper Companies Profile
The Cooper Cos, Inc operates as a medical device company. It operates through the Cooper Vision and Cooper Surgical segments. The Cooper Vision segment develops, manufactures, and markets products for contact lens wearers, which solves vision challenges such as astigmatism, presbyopia, myopia, ocular dryness, and eye fatigues.
Featured Articles
- Get a free copy of the StockNews.com research report on Cooper Companies (COO)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Cooper Companies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cooper Companies and related companies with MarketBeat.com's FREE daily email newsletter.